Article Details

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

Retrieved on: 2021-07-23 10:52:30

Tags for this article:

Click the tags to see associated articles and topics

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader. View article details on hiswai:

Excerpt

ARV-471 is also being studied in a phase 1b combination study alongside Pfizer's blockbuster CDK4/6 inhibitor Ibrance (palbociclib). Under the terms of ...

Article found on: www.pmlive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up